Inclusion Criteria:  Signed informed consent form; Histologically verified diagnosis; Age between 18 and 80 years; If the patient had previously received chemotherapy for these indications, then it should be completed at least 30 days before the first administration of the study drug; ECOG performance 0-2;  Haematology:  ANC ≥ 1,5 х 10(9) /L; Platelets ≥ 100 х 10(9) /L; Hemoglobin ≥ 90 g/L;  Biochemistry:  Creatinine ≤ 1,5 ULN; Total bilirubin ≤ 1,5 ULN; AST/ALT ≤ 2,5 ULN; Alkaline phosphatase ≤ 5 ULN;  8. Life expectancy of at least 6 months from the date of the first drug administration in the study; 9. Ability of the patient to comply with the Protocol requirements.  Exclusion Criteria:  Documented hypersensitivity to empegfilgrastim, filgrastim, pegfilgrastim, and / or their constituent excipients: pegylated drugs, protein recombinant drugs; Systemic use of antibiotics less than 72 hours before the first drug administration in the study; Concurrent or less than 30 days before the start of the study, radiation therapy (with the exception of point radiation therapy for bone metastases); study; Concurrent participation in clinical trials, participation in clinical trials within the previous 30 days, previous participation in this study; Surgical treatment less than 21 days (3 weeks) prior to study enrollment; taking any experimental medications less than 30 days before enrollment in this study; History of bone marrow or hematopoietic stem cell transplantation; Presence of acute or active chronic infections; Other diseases (with the exception of the main one) that could affect the assessment of the severity of the symptoms of the underlying disease: that may mask, enhance, change the symptoms of the underlying disease or cause clinical manifestations and changes in the data of laboratory and instrumental research methods; Inability to administer the drug by intravenous infusion or subcutaneous injection.